Dublin, Ireland, February 19th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of Shaun McNulty, Ph.D., as its Chief Scientific Officer. Dr. McNulty was most recently Chief Scientific Officer at Biosceptre and brings over 25 years of industry experience to Inflection Biosciences.
Dr. McNulty commented “I am delighted to join Inflection Biosciences and look forward to progressing its portfolio of candidates into the clinic. Inflection Biosciences’ approach exploits key interactions between PIM and PI3 kinase pathways. It has been shown that combined inhibition of both pathways by first-in-class IBL-202 may prevent the development of resistance observed for existing PI3 kinase inhibitors, and has the potential to deliver a new treatment option for cancer patients with significant unmet medical needs.”
Darren Cunningham, CEO of Inflection Biosciences, added “Shaun’s appointment comes at an exciting time for Inflection Biosciences as we position our programs for clinical development. His proven track record of successfully progressing candidates from pre-clinical into clinical development make him a great fit and well placed to help us accelerate our development plans.”
Dr. Shaun McNulty is an experienced Chief Scientific Officer, with over 25 years of experience in the biotechnology and pharmaceutical sectors. Having obtained his doctorate in kinase-mediated signalling in glioma cells, from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge, researching kinase-modulated signalling, transcription factor activation and protein expression. Shaun then held drug discovery leadership positions of increasing seniority for Pfizer and GSK, managing small molecule programmes into preclinical development and validating kinases as therapeutic targets. He worked on the Lyrica and Neurontin drug programmes and published more than thirty papers characterising signalling pathways.
Shaun moved into the Biotechnology sector in 2006, joining Syntaxin to direct their oncology discovery portfolio. He then moved to ImmBio, directing scientific collaborations and developing a fundraising strategy. As Biosceptre’s CSO since 2014, Shaun directed a portfolio of oncology candidates, obtaining regulatory approval for two candidates to enter the clinic. He is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com